Assuntos
Biotecnologia/organização & administração , Vacinas contra COVID-19 , COVID-19/prevenção & controle , Desenvolvimento de Medicamentos/organização & administração , Pandemias/prevenção & controle , Biotecnologia/economia , COVID-19/economia , COVID-19/epidemiologia , Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/organização & administração , Cuba/epidemiologia , Desenvolvimento de Medicamentos/economia , Humanos , Cooperação Internacional , Colaboração Intersetorial , Vacinação em Massa/economia , Vacinação em Massa/organização & administração , Pandemias/economiaRESUMO
The coronavirus disease 2019 (COVID-19) pandemic has presented some significant challenges to the scientific community. However, this has also offered opportunities for the pursuit of new scientific activities, and in particular for the field of biotechnology.
Assuntos
Betacoronavirus/patogenicidade , Pesquisa Biomédica/organização & administração , Biotecnologia/organização & administração , Infecções por Coronavirus/epidemiologia , Educação a Distância/organização & administração , Pandemias , Pneumonia Viral/epidemiologia , COVID-19 , Infecções por Coronavirus/psicologia , Humanos , Disseminação de Informação/ética , Disseminação de Informação/métodos , México/epidemiologia , Pneumonia Viral/psicologia , Saúde Pública , SARS-CoV-2 , Rede Social , Estados Unidos/epidemiologiaRESUMO
Forty-three years after it was founded, with billions of dollars invested, the global biotech industry is still not positioned as a mature low-risk sector for the international investor com-munity. Despite the clear commercial success of a number of leading companies and overall growth of the industry's rev-enues, most biotech companies are not profi table and many fail to overcome the formidable barrier constituted by the high cost of the sector's research and development. However, over the last four years, visible signs of change have appeared, which could be harbingers of an approaching turning point in this trend.This article analyzes the historic background of the biotech in-dustry's business models and corporate structures, as well as their impact on the industry's fi nancial framework. It examines recent changes implemented by the sector's main actors-in-cluding young startups, venture capital funds and big pharma companies-to mitigate fi nancial risk associated with develop-ment of new biotechnology products.Finally, it discusses the challenges and opportunities that these tendencies entail for Cuban biotechnology development and proposes adoption of business policies more tolerant of the fi nancial risk inherent in this sector, as a condition for at-tracting venture capital. KEYWORDS Biotechnology, fund raising, risk management, entrepreneurship, Cuba.
Assuntos
Biotecnologia/economia , Indústrias/economia , Biotecnologia/organização & administração , Comércio/economia , Comércio/organização & administração , Cuba , Administração Financeira/economia , Administração Financeira/organização & administração , Humanos , Indústrias/organização & administração , Modelos Organizacionais , Apoio à Pesquisa como Assunto/economia , Apoio à Pesquisa como Assunto/organização & administraçãoAssuntos
Pesquisa Biomédica/organização & administração , Gastroenterologia/organização & administração , Cooperação Internacional , Pesquisa Biomédica/educação , Biotecnologia/organização & administração , Comportamento Cooperativo , Cuba , Atenção à Saúde/organização & administração , Educação Médica/organização & administração , Gastroenterologia/educação , Humanos , Estados UnidosRESUMO
Studies of a bioprocess optimization and monitoring for protein synthesis in animal cells face a challenge on how to express in quantitative terms the system performance. It is possible to have a panel of calculated variables that fits more or less appropriately the intended goal. Each mathematical expression approach translates different quantitative aspects. We can basically separate them into two categories: those used for the evaluation of cell physiology in terms of product synthesis, which can be for bioprocess improvement or optimization, and those used for production unit sizing and for bioprocess operation. With these perspectives and based on our own data of kinetic S2 cells growth and metabolism, as well as on their synthesis of the transmembrane recombinant rabies virus glycoprotein, here indicated as P, we show and discuss the main characteristics of calculated variables and their recommended use. Mainly applied to a bioprocess improvement/optimization and that mainly used for operation definition and to design the production unit, we expect these definitions/recommendations would improve the quality of data produced in this field and lead to more standardized procedures. In turn, it would allow a better and easier comprehension of scientific and technological communications for specialized readers.